Am J Translational Res 2011;3(3):269-274 Review Article Rabbit monoclonal antibody: potential application in cancer therapy
Lifeng Feng, Xian Wang, Hongchuan Jin
Laboratory of Cancer Epigenetics, Biomedical Research Center, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China
Received April 6, 2011; accepted April 19, 2011; Epub April 23, 2011; Published May 15, 2011
Abstract: By targeting antigens specifically, monoclonal antibodies represent a new class of therapeutic agents for the clinical management of various diseases including cancers. Monoclonal antibody technology has been greatly developed by reducing murine content in antibodies to minimize side effects in clinical applications. However, several intrinsic disadvantages of antibodies with murine origin limit the clinical efficacy of monoclonal antibodies based targeted therapy. The development of rabbit monoclonal antibody technology provides an alternative source of monoclonal antibodies with higher specificity and less cost for the development of routine targeted therapy against cancers. (AJTR1104001).
Keywords: Monoclonal antibody, rabbit monoclonal antibody, cancer therapy
Address all correspondence to: Dr. Xian Wang Laboratory of Cancer Epigenetics Biomedical Research Center Sir Runrun Shaw Hospital, School of Medicine Zhejiang University, Hangzhou, 310016, China Tel: +86 571 8600 6926; Fax: +85 571 8600 5145 Email: email@example.com;
Dr. Hongchuan Jin Laboratory of Cancer Epigenetics Biomedical Research Center Sir Runrun Shaw Hospital, School of Medicine Zhejiang University, Hangzhou, 310016, China Tel: +86 571 8600 6366; Fax: +86 571 8600 6145 Email: firstname.lastname@example.org